Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. News
Regeneron Pharmaceuticals, Inc. Quantitative Score
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Regeneron Pharmaceuticals, Inc. Earnings & Revenue
Regeneron Pharmaceuticals, Inc. Financials
Table Compare
Compare REGN metrics with: | |||
|---|---|---|---|
Earnings & Growth | REGN | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | REGN | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | REGN | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | REGN | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Regeneron Pharmaceuticals, Inc. Income
Regeneron Pharmaceuticals, Inc. Balance Sheet
Regeneron Pharmaceuticals, Inc. Cash Flow
Regeneron Pharmaceuticals, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Buy |
| Return on Assets | Strong Buy |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Regeneron Pharmaceuticals, Inc. Executives
| Name | Role |
|---|---|
| Dr. Leonard S. Schleifer M.D., Ph.D. | Co-Founder, President, Chief Executive Officer & Co-Chairman |
| Dr. George D. Yancopoulos M.D., Ph.D. | Co-Founder, President, Chief Scientific Officer & Co-Chairman |
| Mr. Daniel P. Van Plew | Executive Vice President and GM of Industrial Operations & Product Supply |
| Mr. Joseph J. LaRosa | Executive Vice President, General Counsel & Secretary |
| Dr. Andrew J. Murphy Ph.D. | Executive Vice President of Research |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Leonard S. Schleifer M.D., Ph.D. | Co-Founder, President, Chief Executive Officer & Co-Chairman | 1953 | 8.18M | |
| Dr. George D. Yancopoulos M.D., Ph.D. | Co-Founder, President, Chief Scientific Officer & Co-Chairman | 1960 | 7.76M | |
| Mr. Daniel P. Van Plew | Executive Vice President and GM of Industrial Operations & Product Supply | Male | 1973 | 2.01M |
| Mr. Joseph J. LaRosa | Executive Vice President, General Counsel & Secretary | Male | 1959 | 1.75M |
| Dr. Andrew J. Murphy Ph.D. | Executive Vice President of Research | 1959 | 1.68M |
Regeneron Pharmaceuticals, Inc. Insider Trades
| Date | 11 Jul |
| Name | LAROSA JOSEPH J |
| Role | EVP General Counsel and Secret |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 1866 |
| Date | 1 Jul |
| Name | McCourt Marion |
| Role | EVP Commercial |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 1137 |
| Date | 1 Jul |
| Name | McCourt Marion |
| Role | EVP Commercial |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 1137 |
| Date | 1 Jul |
| Name | McCourt Marion |
| Role | EVP Commercial |
| Transaction | Disposed |
| Type | M-Exempt |
| Shares | 1137 |
| Date | 1 Jul |
| Name | RYAN ARTHUR F |
| Role | Director |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 3 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 11 Jul | LAROSA JOSEPH J | EVP General Counsel and Secret | Disposed | S-Sale | 1866 |
| 1 Jul | McCourt Marion | EVP Commercial | Acquired | M-Exempt | 1137 |
| 1 Jul | McCourt Marion | EVP Commercial | Disposed | S-Sale | 1137 |
| 1 Jul | McCourt Marion | EVP Commercial | Disposed | M-Exempt | 1137 |
| 1 Jul | RYAN ARTHUR F | Director | Disposed | S-Sale | 3 |